Trial Profile
Phase 1b Study of CS-7017 in Combination With Carboplatin/Paclitaxel in Chemotherapy-naive Subjects With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Efatutazone (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Inc
- 11 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Sep 2010 New trial record